Simplifying Progress

Welcome to Sartorius
July 2024

Our ambition: Better health for more people

2Mission

We empower scientists and engineers to simplify andaccelerate progress in life science and bioprocessing,enabling the development of new and better therapies
and more affordable medicine.

VisionWe are a magnet and dynamic platform for pioneers
and leading experts in our field. We bring creative minds
together for a common goal: technological breakthroughsthat lead to better health for more people.

Sartorius in 2023 numbers~€3.4bn

Sales revenue

28.3%

Profit margin114,500+

Employees

60+

Locations worldwide~€560mn

150+

Years of experience2045

1 Underlying EBITDA margin

3

Investments in capacities
Target for climate neutrality

14,500 employees united by strong values

Sustainability

Openness

Enjoyment

Growing profitably andacting responsibly towards
all stakeholders

Driving change
and progressinternally and externally

Working in an energetic
and rewarding
environment

113

Nationalities

54%
39%

Women

55%

4

Younger than
40 years

Joined since
2019Two divisions with a clear focus on the life science industry

Offers a wide array ofinnovative technologies
for the manufacture ofbiopharmaceuticals andvaccines as well as celland gene therapeutics

79%

Sales 2023

21%

Bioprocess Solutions
Division~€3.4bn

Lab Products & Services
Division~85%
with life sciencecustomers

5

Specializes inequipment andtechnologies for life
science research andpharmaceuticallaboratories

Enabling the discovery and production of biopharmaceuticals
Bioprocess Solutions Division

Molecule
development

Cell line andprocess development
Quality | Testing | Validation

Lab Products & Services Division

6Upstream &downstream production

The promises of biologics: From established to new concepts
Advantages

What are biopharmaceuticals?

Consist ofcomplex molecules

Obtained from living cells incell culture processes

Administered mainly
intravenously

Target only diseased cells▪

Have fewer side effects▪

Allow first-time or improved treatment ofillnesses, e.g. cancer, multiple sclerosis,
rheumatism

1796

1818

1982

1986

2012 / 20172020

Smallpox
VaccineBloodTransfusion

HumanInsulin

Monoclonal
Antibodies

Cell & Gene
TherapymRNA
VaccineEstablished biopharmaceuticals

7▪

Next generation

Many biotech medications are highly effective, but very expensive

Rheumatism

Blood cancer

Hemophilia

Monoclonal antibodies

CAR-T cell therapy

Gene therapy~€12,000~€280,000~$3.5mn

Annual cost of treatment in GER

8Cost per treatment in Europe

Cost per treatment in the USA

Only one out of 10,000 new drug candidates reaches the market
Drug discovery

Process development>€2bnAverage costs of developing
a successful drugMarket approval

Probability of clinical success(Phase I to approval)

Schematic example of biologic drug discovery with data from the Association of the British Pharmaceutical Industry

9~10%

Commercial production>10 years

From drug discovery
to approvalHelping researchers in the labs to accelerate drug discovery
Our ambition
Reduce costly trial & error

Our solutions
Powerful bioanalytical tools and lab essentials

Understand diseases
Conduct experiments
Live cell analysis

Cell characterization

Protein analysis

Cell selection

Pipetting

Weighing

Filtration

Water purification

Make better use of data
Identify molecules

Develop new drugs

10

Once discovered also the manufacture of biologics remains complex

11

Providing technologies to increase productivity in bioprocessing
Our ambition
More efficient bioprocessing

Our solutions
Technologies for all phases of drug manufacturingSet up safe andflexible processes
Increase resource andmaterial efficiency

Bioreactors & fermenters

Media & reagents

Reduce investments
Enhance product yield

12

Chromatography

Filtration

Fluid management

Data analysis

Offering integrated end-to-end manufacturing solutions
Upstream

Production ofthe desired
drug

Cell culture media &preparation

Seed
cultivation

Scale-up

Production

Downstream

Isolation andfilling of thedesired drug
Finalfilling

13

Cryopreservation

Sterilefiltration

Concentration

Virus clearance& filtration

Chromatography

Clarification &centrifugation

Helping customers to reduce their environmental footprint

Single-usetechnologies

Biostat® STR Bioreactors

14Processintensification

Linkit® AXResolute® BioSMB

Dataanalytics▪

No water-/energyintensive cleaning▪

Less cleanroom space,less energy usage▪

Higher yields

Ambr® 250HT Perfusion

Umetrics Suite

Cell and gene therapies: New modalities, new challenges

Next generation biopharmaceuticals
Viral Vectors

mRNA

Stem Cells

ExosomesDNA

New Vaccines

Enabling CGT: High need for innovation

Robustness of production process
Yields, productivity, cost-per-dose

Innovative treatments for patients

6,000+~60

Candidates in development1

Regulation under development

Approved therapies worldwide

1 GlobalData, October 2023, CGT = Cell & Gene Therapies

15

Time-to-market

Manufacturing close to patients

Creating a technology platform for cell and gene therapy applications

BiologicalIndustries

Cell culture
media

16

CellGenix

Growth factors
and cytokines

XellMedia andsupplements

Albumedix

RecombinantAlbumin

Polyplus

Transfection
reagents andplasmid DNA

Up & downstream solutions

Cell line development,
plasmid design &manufacturing andtesting services

How we innovate

Own Product Development
in areas of core competencies

Separation

Cell cultivationtechnologies

Lab analysis

Automation

Recent focus; selected projects

17Acquisitionsof complementary technologies

Media & reagents

Chromatography

Bioanalytical instruments

Cooperations

with partners leading in their fields

Nanoparticles

Bioprinting

Artificial
intelligence

Cell models

Resilient global setup, well prepared for further growth

Customer proximity

Redundant capacity

Ann Arbor, Michigan, USA
Bioanalytical products & services

Songdo, South Korea
Media, bags, filtration, labs, training~12 %Operational excellence

Global resilience

Expected capex
ratio 2024
Göttingen, Germany
Filter production, product development

Expansion of production & R&D capacities; selected current projects

18Freiburg, Germany
Cell culture components

Aubagne, France
Clean rooms, product development, labs

Strong financial track record; profitable growth

~15%

4100
3900

High volatility during and post pandemic

Ø Annual growth
2014-2023

59,5~€3.4bn

3700
3500

2900
2700
2500
2300

34.1

2100
1900
1700

1100

53,5
51,53100

1300

55,5

on prior-year 49,5level, with 47,545,5
bandwith of +/-43,541,5
lsd % growth 39,53300

1500

57,5

~€890m

900

21.0

700
500

25.0

23.6

25.1

25.9

27.133.8

37,535,5

29.6

28.3

33,5
31,529,5Margin
27%-29%27,525,5
23,5
21,5

300

19,5100

17,5

2014
Sales revenue

2015

2016

2017

2018

2019

EBITDA1 margin in %Sales CAGR for continued operations, in constant currencies; EBITDA margin excluding extraordinary items

19

2020

2021

2022

2023

2024e

Ambitious midterm targets backed by strong market fundamentals

Clear strategy

Expanding market forbiopharmaceuticals incl.
biosimilars

Competitive, integrated
product portfolio

Dynamic market segment ofnovel therapies

Strong, customer-focused
teamHigh need for innovation

Powerful and resilient
production and R&D
infrastructure

1 Thereof around a fifth through acquisitions

20Ambition to 2028

Growing and aging
world population

Low double-digit
avg. annual sales growth1~34%
Underlying EBITDA margin

Broad and ambitious sustainability agenda in implementation

2030 mid-term targets~10%

av. reduction of CO2eq emission
intensity p.a. (Scopes 1-3)

>75%

revenue with products designed
according to circularity principles22045 long-term target

Zero

avoidable1 emissionsin Scopes 1 and 2

Zerooperational waste tolandfill

100%

electricity fromrenewable sources

35

Net-zeroemissions
Decarbonization of the entire
supply chain in collaboration withsuppliers and customers

av. annual Employee
Net Promoter Score

1 Process emissions from membrane manufacturing are currently considered unavoidable based on available technology, 2 Including product and transport packaging

21

Simplifying Progress

Sartorius AG
Corporate Communications & IR
Otto-Brenner-Straße 20
37079 Göttingen
Germany